Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Solvent-free gadolinium contrast agents

a gadolinium contrast agent, solvent-free technology, applied in the direction of medical preparations, emulsion delivery, dispersed delivery, etc., can solve the problems of insufficient resolution of toxicity problems, inability to use gadolinium metal in vivo, inability to completely solve toxicity problems, etc., to reduce the amount of intentional excess pentetic acid, reduce the variability of parameters, and cause skin irritation

Inactive Publication Date: 2019-09-05
INVENTURE LLC
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides safe and effective contrast agents for enhancing magnetic resonance images of body organs and tissues. Specifically, a ligand-gadolinium complex is designed to have improved safety, consistent results, and absence of solvent contaminants.

Problems solved by technology

Consequently, medical contrast agents with a large pH range in the product specification present a safety concern regarding product stability and the potential for formation the release toxic Gd(III) from the complex.
The large pH range in the drug product is linked to the use of solvents in the drug purification process, which tends to remove ligand in an unpredictable fashion.
The synthetic methods attempted in the past to prepare paramagnetic metal chelates have one or more drawbacks such as the use of large excess of ligand to reduce free Gd(III) ion; or the need to carry out extensive solvent purification of product due to impurities in the original reagents.
Ironically, the biocompatible solvents used to purify the drug product can complex with the impurities they are meant to remove.
Thus, the use of gadolinium metal in vivo, for example gadolinium chloride or gadolinium oxide, is not safe and a water-soluble chelate of gadolinium must be used.
While a water soluble chelated gadolinium-based contrast agent is safer to inject in patients, the toxicity issues are not entirely solved.
However, Gd(III) ion, even if it does not form a water-insoluble compound, can still be toxic, since the reactivity of Gd(III) is very similar to Ca(II), and Ca(II) is ubiquitous in chemical pathways in the mammalian body.
Beyond this threshold concentration, any further increase in concentration results in little improvement in contrast enhancement.
Gd(III) can compete with Ca(II) in the chemical pathways of biological systems, and this substitution potential results in gadolinium toxicity to organisms.
This chelate effect can be compromised by the presence of solvent, which can form binding spheres with solvent rather than water.
Stronger acid conditions clearly results in lower complex stability.
There are additional ionic competitors besides protons that can affect complex stability.
The fact that transmetallation of gadolinium complexes results in the formation of a more unstable metal complex implies that the synthesis methodology can impact the magnitude of transmetallation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Solvent-free gadolinium contrast agents
  • Solvent-free gadolinium contrast agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

ree Gadopentetate Dimeglumine

Raw Materials

[0176]

Raw MaterialMole Ratio1DTPA12Gd2O30.4963Water2.2V1 (DTPA)4Meglumine0.992

Preparation of DTPA Solution

[0177]1. Heat reactor to 25-30° C.[0178]2. Charge water[0179]3. Begin stirring (stir unless otherwise indicated, nominal rate 300 rpm)[0180]4. Charge 10% of the DTPA[0181]5. Stir until uniformly distributed in the water[0182]6. If all the DTPA is charged, then go to step 8[0183]7. Go to step 4[0184]8. Stir 10 min

Preparation of Gadolinium: DTPA Complex

[0185]9. Charge 25% by weight of the Gadolinium oxide[0186]10. Stir until uniformly distributed[0187]11. If all the Gadolinium oxide is charged then go to step 13[0188]12. Go to step 9[0189]13. Stir 10 min[0190]14. Raise temperature to 95+ / −2° C.[0191]15. Stir 3 hrs.[0192]16. Check clarity[0193]17. If not clear continue for 1 hr, go to step 16[0194]18. If clear, continue 1 hr and then cool to 40-45° C.[0195]19. If precipitate forms, heat to 95+ / −2° C. and stir for 1 hr, go to step 16

Verify C...

example 2

ree Gadoterate Meglumine

[0238]Preparation of DOTA Solution[0239]1. Heat reactor to 25-30° C.[0240]2. Charge water[0241]3. Begin stirring (stir unless otherwise indicated, nominal rate 300 rpm)[0242]4. Charge 10% of the DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)[0243]5. Stir until uniformly distributed in the water[0244]6. If all the DOTA is charged, then go to step 8[0245]7. Go to step 4[0246]8. Stir 10 min

[0247]Preparation of Gadolinium: DOTA Complex[0248]9. Charge 25% by weight of the Gadolinium oxide[0249]10. Stir until uniformly distributed[0250]11. If all the Gadolinium oxide is charged then go to step 13[0251]12. Go to step 9[0252]13. Stir 10 min[0253]14. Raise temperature to 95+ / −2° C.[0254]15. Stir 3 hrs.[0255]16. Check clarity[0256]17. If not clear continue for 1 hr, go to step 16 (this step took about 12 hours, slower than Magnevist synthesis)[0257]18. If clear, continue 1 hr and then cool to 40-45° C.[0258]19. If precipitate forms, heat to 95+ / −2° C. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are complexes of gadolinium metal, ligand and meglumine that are substantially free of non-aqueous solvents. In particular, solvent-free complexes of 1) gadopentetate dimeglumine and 2) gadoterate meglumine are disclosed and methods of their preparation are disclosed. In addition, methods are disclosed for purifying reactants, monitoring and controlling pH, quantifying the free gadolinium content, quantifying the concentration of gadolinium-ligand complex in aqueous solution, and procedures for producing a drug product in one step. The one step process eliminates the need to dry the gadolinium-ligand complex, which is typically highly hygroscopic. The one step process includes purification steps that do not require the use of non-aqueous solvents.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. application Ser. No. 15 / 855,570, filed Dec. 27, 2017, which claims benefit of U.S. Provisional Application No. 62 / 439,893, filed Dec. 29, 2016, both of which are hereby incorporated by reference in their entireties.TECHNICAL FIELD[0002]The present disclosure relates generally to metal chelates, particularly those of lanthanide metals, and in one specific embodiment, those of Gd(III), which are useful as contrast agents in magnetic resonance imaging for therapeutic and diagnostic applications, as well as clinical and biomedical research applications.BACKGROUND OF THE INVENTION[0003]Magnetic resonance imaging (MRI) is a powerful diagnostic method that yields three-dimensional images of body tissues in vivo. The tissue features obtained are the result of variations in the distribution of water in these tissues. MRI contrast agents administered prior to imaging alter the relaxation times of p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K49/10
CPCA61K49/105A61K2123/00A61K49/1806A61K49/108A61K49/18A61K49/106A61K49/101A61K49/103
Inventor DESLAURIERS, RICHARDBALFOUR, JONATHANMILBOCKER, MICHAEL
Owner INVENTURE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products